Structures by: Resende J. A.
Total: 43
Compound 7
C17H12O3S1
Organic & biomolecular chemistry (2011) 9, 11 4315-4322
a=9.713(2)Å b=11.179(2)Å c=13.663(3)Å
α=90° β=109.59(3)° γ=90°
C29H19F18NdO8S
C29H19F18NdO8S
New Journal of Chemistry (2020) 44, 33 14161-14170
a=10.0548(8)Å b=13.6467(12)Å c=14.5545(13)Å
α=103.029(4)° β=93.009(4)° γ=101.760(4)°
C27H17F18NdO9S,H2O
C27H17F18NdO9S,H2O
New Journal of Chemistry (2020) 44, 33 14161-14170
a=11.6815(11)Å b=12.1673(11)Å c=15.3934(15)Å
α=69.140(4)° β=86.876(4)° γ=67.194(4)°
C25H26BrN3O5
C25H26BrN3O5
RSC Advances (2012) 2, 30 11438
a=5.8640(2)Å b=15.2666(18)Å c=26.181(2)Å
α=90° β=90° γ=90°
C24H24Br1N3O5
C24H24Br1N3O5
RSC Advances (2012) 2, 30 11438
a=5.1446(3)Å b=13.3386(10)Å c=33.974(3)Å
α=90° β=90° γ=90°
C19H21NO7
C19H21NO7
RSC Adv. (2015) 5, 116 96222
a=5.8376(2)Å b=11.9174(4)Å c=12.2331(5)Å
α=90° β=94.745(4)° γ=90°
C19H19N3O7
C19H19N3O7
RSC Adv. (2015) 5, 116 96222
a=5.9539(2)Å b=5.7856(2)Å c=25.9610(11)Å
α=90° β=91.139(4)° γ=90°
C63H48ErO7P
C63H48ErO7P
RSC Adv. (2017) 7, 30 18239
a=11.4558(5)Å b=12.2566(5)Å c=18.7593(8)Å
α=87.5699(13)° β=84.3897(14)° γ=77.4603(13)°
8-hydroxy-2-(p-tolylthio)naphthalene-1,4-dione
C17H12O3S1
Organic & biomolecular chemistry (2011) 9, 11 4315-4322
a=8.9234(7)Å b=8.6499(7)Å c=17.8425(8)Å
α=90° β=103.821(7)° γ=90°
C51H33F18NdO8P2
C51H33F18NdO8P2
New Journal of Chemistry (2020) 44, 33 14161-14170
a=13.1817(7)Å b=13.6362(6)Å c=30.7235(16)Å
α=90° β=90.6330(18)° γ=90°
Isoquinoline
C19H13Br2ClN2O4
RSC Adv. (2017) 7, 30 18311
a=20.5261(10)Å b=9.0318(5)Å c=10.5375(6)Å
α=90° β=90° γ=90°
Isoquinoline
C19H14BrClN2O4
RSC Adv. (2017) 7, 30 18311
a=14.560(3)Å b=10.207(2)Å c=25.110(5)Å
α=90° β=102.18(3)° γ=90°
C19H19Cu1F12N4O5
C19H19Cu1F12N4O5
Dalton transactions (Cambridge, England : 2003) (2011) 40, 41 10843-10850
a=8.6543(2)Å b=12.1291(3)Å c=12.755(3)Å
α=77.660(2)° β=85.330(2)° γ=74.219(2)°
C59H36Co2N8O12
C59H36Co2N8O12
Dalton transactions (Cambridge, England : 2003) (2013) 42, 15 5462-5470
a=8.2264(4)Å b=11.0110(7)Å c=15.2164(8)Å
α=72.632(5)° β=78.902(4)° γ=82.156(5)°
C37H26CoN2O6
C37H26CoN2O6
Dalton transactions (Cambridge, England : 2003) (2013) 42, 15 5462-5470
a=7.5420(4)Å b=12.2546(8)Å c=15.9401(11)Å
α=96.822(5)° β=90.829(5)° γ=90.052(5)°
Compound colaupy
C30H20CoN2O6,CH4O
Dalton transactions (Cambridge, England : 2003) (2013) 42, 15 5462-5470
a=14.433(3)Å b=10.594(2)Å c=17.946(4)Å
α=90° β=101.47(3)° γ=90°
C30H18CoN2O6
C30H18CoN2O6
Dalton transactions (Cambridge, England : 2003) (2013) 42, 15 5462-5470
a=19.559(5)Å b=14.772(5)Å c=8.378(5)Å
α=90.000(5)° β=90.000(5)° γ=90.000(5)°
C32H18CoN2O6,3(C4H8O)
C32H18CoN2O6,3(C4H8O)
Dalton transactions (Cambridge, England : 2003) (2013) 42, 15 5462-5470
a=9.1959(5)Å b=20.5009(13)Å c=9.7022(7)Å
α=90° β=90° γ=90°
C16H12N2O8S,2(H2O)
C16H12N2O8S,2(H2O)
CrystEngComm (2013) 15, 42 8422
a=10.4318(6)Å b=16.6580(10)Å c=10.1656(5)Å
α=90.00° β=90.00° γ=90.00°
C20H20N2O8S
C20H20N2O8S
CrystEngComm (2013) 15, 42 8422
a=7.5660(3)Å b=11.5600(4)Å c=12.2620(4)Å
α=74.727(2)° β=76.510(2)° γ=78.804(2)°
C16H16Ca1N2O11S1
C16H16Ca1N2O11S1
CrystEngComm (2013) 15, 42 8422
a=15.876(3)Å b=23.562(5)Å c=12.514(3)Å
α=90° β=117.77(3)° γ=90°
C24H26N2O4
C24H26N2O4
CrystEngComm (2014) 16, 15 3168
a=11.2908(3)Å b=12.2293(3)Å c=14.9933(4)Å
α=90° β=91.389(2)° γ=90°
C48H54N4O9
C48H54N4O9
CrystEngComm (2014) 16, 15 3168
a=13.477(3)Å b=16.515(3)Å c=19.139(4)Å
α=90° β=94.16(3)° γ=90°
1-Anilino-5-methyl-1<i>H</i>-1,2,3-triazole-4-carboxylic acid monohydrate
C10H10N4O2,H2O
Acta Crystallographica Section E (2019) 75, 6 738-741
a=7.2288(14)Å b=6.8265(14)Å c=23.922(5)Å
α=90° β=98.69(3)° γ=90°
C16H9NO3
C16H9NO3
Acta Crystallographica Section E (2002) 58, 9 o985-o987
a=7.493(5)Å b=21.276(5)Å c=8.024(5)Å
α=90.000° β=113.508(5)° γ=90.000°
C2H4N2NiS4
C2H4N2NiS4
Acta Crystallographica Section E (2003) 59, 2 m77-m79
a=7.1310(4)Å b=12.9170(8)Å c=10.9590(5)Å
α=90° β=130.293(3)° γ=90°
C20H29F1O3
C20H29F1O3
Acta Crystallographica Section E (2003) 59, 12 o1935-o1937
a=6.0284(4)Å b=10.850(2)Å c=26.921(3)Å
α=90° β=90° γ=90°
Grossular-andradite
Ca3Al1.338Fe0.662Si3O12
Acta Crystallographica, Section E (2005) 61, 12 i265-i267
a=11.9220(10)Å b=11.9220(10)Å c=11.9220(10)Å
α=90.0° β=90.0° γ=90.0°
C9H8N2O2
C9H8N2O2
Acta Crystallographica Section E (2003) 59, 5 o723-o725
a=5.6672(3)Å b=18.0609(11)Å c=8.1949(5)Å
α=90° β=99.135(3)° γ=90°
1,2-Dihydroxy-2-(3-methylbut-2-enyl)-3-oxo-2,3-dihydro-1<i>H</i>-indene-1- carboxylic acid monohydrate
C15H16O5,H2O
Acta Crystallographica Section E (2010) 66, 2 o341
a=9.5514(7)Å b=5.7762(5)Å c=13.1324(9)Å
α=90° β=92.126(12)° γ=90°
Aqua(4,4-bipyridine-κ<i>N</i>)bis(1,4-dioxo-1,4-dihydronaphthalen-2-olato- κ^2^<i>O</i>^1^,<i>O</i>^2^)zinc 4,4'-bipyridine monosolvate dihydrate
C30H20N2O7Zn,C10H8N2,2(H2O)
Acta Crystallographica Section E (2011) 67, 11 m1489-m1490
a=8.1448(16)Å b=14.179(3)Å c=15.910(3)Å
α=73.90(3)° β=88.59(3)° γ=89.53(3)°
<i>tert</i>-Butyl <i>N</i>-{3-[(3-chloro-1,4-dioxo-1,4- dihydronaphthalen-2-yl)amino]propyl}carbamate
C18H21ClN2O4
Acta Crystallographica Section E (2012) 68, 8 o2361
a=5.5172(2)Å b=16.6134(6)Å c=19.6758(6)Å
α=90° β=95.709(3)° γ=90°
C39H54N6O8S
C39H54N6O8S
Crystal Growth & Design (2015) 15, 11 5233
a=14.633(5)Å b=9.370(5)Å c=15.966(5)Å
α=90.000(5)° β=114.871(5)° γ=90.000(5)°
C38H57ClN6O8
C38H57ClN6O8
Crystal Growth & Design (2015) 15, 11 5233
a=14.2750(2)Å b=9.6424(5)Å c=16.008(2)Å
α=90° β=111.617(12)° γ=90°
C38H53IN6O6
C38H53IN6O6
Crystal Growth & Design (2015) 15, 11 5233
a=14.3578(7)Å b=9.4796(4)Å c=15.9818(13)Å
α=90° β=111.131(7)° γ=90°
Nevirapine hemihydrate
2(C15H14N4O),H2O
Crystal Growth & Design (2007) 7, 10 2016-2023
a=8.8541(3)Å b=32.115(5)Å c=10.0644(11)Å
α=90° β=104.036(7)° γ=90°
C41H36Cu2N12O9,CH4O
C41H36Cu2N12O9,CH4O
Crystal Growth & Design (2015) 15, 3 1027
a=12.4202(6)Å b=13.8430(6)Å c=13.9603(8)Å
α=90° β=115.446(6)° γ=90°
C20H16CuN6O4,5(H2O)
C20H16CuN6O4,5(H2O)
Crystal Growth & Design (2015) 15, 3 1027
a=11.3128(16)Å b=11.3128(16)Å c=34.111(7)Å
α=90° β=90° γ=120°
C33H18N2O3
C33H18N2O3
The Journal of organic chemistry (2016) 81, 13 5525-5537
a=10.6689(4)Å b=10.9978(5)Å c=11.8961(6)Å
α=81.299(2)° β=66.4970(10)° γ=62.7020(10)°
Nevirapine hemi-ethyl acetate solvate
C15H14N4O,0.5(C4H8O2)
Crystal Growth & Design (2007) 7, 10 2016-2023
a=7.9249(16)Å b=8.6013(17)Å c=12.7431(25)Å
α=95.43(3)° β=90.16(3)° γ=112.33(2)°
Nevirapine hemihydrate
2(C15H14N4O),H2O
Crystal Growth & Design (2007) 7, 10 2016-2023
a=8.8541(3)Å b=32.115(5)Å c=10.0644(11)Å
α=90° β=104.036(7)° γ=90°
C38H55BrN6O7
C38H55BrN6O7
Crystal Growth & Design (2015) 15, 11 5233
a=14.3053(7)Å b=9.7478(4)Å c=15.84700(10)Å
α=90° β=111.404(7)° γ=90°
Grossular
Al1.338Ca3Fe0.662O12Si3
Acta Crystallographica, Section E (2005) 61, i265-i267
a=11.9220Å b=11.9220Å c=11.9220Å
α=90° β=90° γ=90°